Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
David Gomez Almaguer, Hospital Universitario Dr. Jose E. Gonzalez
ClinicalTrials.gov Identifier:
NCT01380587
First received: June 22, 2011
Last updated: August 26, 2013
Last verified: August 2013

June 22, 2011
August 26, 2013
November 2010
September 2012   (final data collection date for primary outcome measure)
  • Number of patients with poor prognosis and high levels of XCL1 [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
  • Number of patients with poor prognosis and high levels of cytokines [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.
Same as current
Complete list of historical versions of study NCT01380587 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

whole blood, serum, white cells, blasts

Non-Probability Sample

We will invite patients with newly diagnosed acute lymphoblastic leukemia , who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.

Acute Lymphoblastic Leukemia
Not Provided
Acute Lymphoblastic Leukemia
We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
September 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion Criteria:

  • Patients with prior treatment with chemotherapeutic agents.
  • Patients treated with immunosuppressants.
  • Patients under 12 months old.
  • Patients with a diagnosis or history of autoimmune diseases.
  • Patients with a diagnosis or history of immunosuppressive diseases.
  • Patients who do not agree to sign a Letter of Informed Consent.
Both
1 Year and older
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
NCT01380587
XCL1 in ALL
No
David Gomez Almaguer, Hospital Universitario Dr. Jose E. Gonzalez
Hospital Universitario Dr. Jose E. Gonzalez
Not Provided
Principal Investigator: Cesar H Gutierrez Aguirre, MD Hospital Universitario Dr. Jose E. Gonzalez UANL
Hospital Universitario Dr. Jose E. Gonzalez
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP